Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | CAR-T: myeloma toxicities

Mohamad Mohty • 30 Mar 2020
Multiple Myeloma Dexamethasone

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines why the toxicities witnessed in patients with multiple myeloma vary compared to those seen in other hematological malignancies. Specifically, the heavy use of dexamethasone in this population is highlighted. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mohamad Mohty

Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Mohamad Mohty • 7 Dec 2025
Advances in GvHD management presented at ASH 2025
5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS
3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Mohamad Mohty • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Mohamad Mohty • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Mohamad Mohty • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Mohamad Mohty • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals